Results 1–48 of 5084 for Bristol-Myers Squibb Company.
  • IXAMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY
    Bristol-Myers Squibb Company
    IXAMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY
  • IXEMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY
    Bristol-Myers Squibb Company
    IXEMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY
  • IVORY A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY
    Bristol-Myers Squibb Company
    IVORY A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY
  • IXAMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY
    Bristol-Myers Squibb Company
    IXAMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY
  • IXEMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY
    Bristol-Myers Squibb Company
    IXEMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY
  • IE85228
    Bristol-Myers Squibb Company
  • IE86401
    Bristol-Myers Squibb Company
  • IE86402
    Bristol-Myers Squibb Company
  • IE107886
    Bristol-Myers Squibb Company
  • IE165038
    Bristol-Myers Squibb Company
  • IE175451
    Bristol-Myers Squibb Company
  • IE204169
    Bristol-Myers Squibb Company
  • IE210847
    Bristol-Myers Squibb Company
  • IE211052
    Bristol-Myers Squibb Company
  • IE214237
    Bristol-Myers Squibb Company
  • IE216666
    Bristol-Myers Squibb Company
  • IE225353
    Bristol-Myers Squibb Company
  • IE225354
    Bristol-Myers Squibb Company
  • IE225355
    Bristol-Myers Squibb Company
  • IE225389
    Bristol-Myers Squibb Company
  • IE225956
    Bristol-Myers Squibb Company
  • IE230515
    BRISTOL-MYERS SQUIBB COMPANY
  • IE231453
    BRISTOL-MYERS SQUIBB COMPANY
  • IE231478
    BRISTOL-MYERS SQUIBB COMPANY
  • IE232511
    BRISTOL-MYERS SQUIBB COMPANY
  • IE232721
    BRISTOL-MYERS SQUIBB COMPANY
  • IE234348
    BRISTOL-MYERS SQUIBB COMPANY
  • IE234361
    BRISTOL-MYERS SQUIBB COMPANY
  • IE234647
    BRISTOL-MYERS SQUIBB COMPANY
  • IE237765
    BRISTOL-MYERS SQUIBB COMPANY
  • IE239393
    Bristol-Myers Squibb Company
  • IE239828
    BRISTOL-MYERS SQUIBB COMPANY
  • IE240325
    BRISTOL-MYERS SQUIBB COMPANY
  • AT125695
    BRISTOL-MYERS SQUIBB COMPANY
  • BMS &
    BRISTOL-MYERS SQUIBB COMPANY
    BMS &
  • AT154722
    BRISTOL-MYERS SQUIBB COMPANY
  • BMS GENERX
    BRISTOL-MYERS SQUIBB COMPANY
    BMS GENERX
  • APOTHECON
    BRISTOL-MYERS SQUIBB COMPANY
    APOTHECON
  • ZERIT
    BRISTOL-MYERS SQUIBB COMPANY
    ZERIT
  • SERZONE
    BRISTOL-MYERS SQUIBB COMPANY
    SERZONE
  • NEUROSCIENCE
    BRISTOL-MYERS SQUIBB COMPANY
    NEUROSCIENCE
  • NEUROSCIENCE BRISTOL-MYERS SQUIBB COMPANY
    BRISTOL-MYERS SQUIBB COMPANY
    NEUROSCIENCE BRISTOL-MYERS SQUIBB COMPANY
  • VANLEV
    BRISTOL-MYERS SQUIBB COMPANY
    VANLEV
  • TEQUIN
    BRISTOL-MYERS SQUIBB COMPANY
    TEQUIN
  • VIDEX
    BRISTOL-MYERS SQUIBB COMPANY
    VIDEX
  • REYATAZ
    BRISTOL-MYERS SQUIBB COMPANY
    REYATAZ
  • REYATAZ
    BRISTOL-MYERS SQUIBB COMPANY
    REYATAZ
  • REYATAZ
    BRISTOL-MYERS SQUIBB COMPANY
    REYATAZ